Community/Retail

Another bill, another day for the erosion of pharmacy benefits as a means of affording a prescription.

Brad Cochran of Cardinal Health explains the One Voice Initiative, which aims to bolster independent pharmacies.

Donanemab-azbt shows sustained benefits in slowing cognitive decline in Alzheimer disease, emphasizing the value of early intervention and treatment.

New research highlights a surge in pediatric pneumococcal pneumonia cases post COVID-19, urging a shift toward supportive treatment strategies.

Explore effective strategies for safely discontinuing benzodiazepines and sedative-hypnotics, addressing risks and enhancing patient care in older adults.

Collaborating with local organizations strengthens trust and can influence vaccination uptake.

Research reveals body fat percentage and waist circumference are more accurate predictors of mortality risk than BMI, highlighting flaws in traditional weight assessments.

WHO reclassifies hepatitis D as carcinogenic, urging global action to combat viral hepatitis and reduce liver cancer risk.

Continuing a trend observed since the end of the COVID-19 pandemic, vaccine coverage among kindergartners declined in the 2024-2025 school year, according to CDC data.

In the SURPASS-CVOT clinical trial, tirzepatide was non-inferior to dulaglutide in a composite score of cardiovascular outcomes in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD).

BPA exposure accelerates ER+ breast cancer growth, impacting treatment efficacy and altering the pharmacist's role in therapy administration.

Researchers reveal that saliva tests for insulin levels offer a noninvasive method to predict type 2 diabetes and obesity risks effectively.

Mona El-Mouwfi explores how pharmacists enhance hydroxyurea therapy for sickle cell disease, improving patient outcomes and addressing treatment barriers effectively.

Amy C. Nieto explains essential guidelines for managing diabetes during Ramadan, ensuring safe fasting practices and optimal health for patients.

Pharmacies enhance public health by providing essential back-to-school vaccinations and addressing vaccine hesitancy, ensuring community protection this fall.

The FDA approves aceclidine ophthalmic solution 1.44%, the first aceclidine eye drop for presbyopia, offering a new solution for millions struggling with near vision loss.

FDA approves inclisiran as a monotherapy to effectively lower low-density lipoprotein cholesterol in adults with hypercholesterolemia, enhancing heart disease prevention strategies.

The approval builds upon concizumab’s previous December 2024 clearance and allows for treatment in patients with hemophilia A or B, both with or without inhibitors.

Ivermectin shows promise in reducing malaria cases, enhancing vector control, and highlighting pharmacists' vital roles in public health strategies.

Kirk Knowlton, MD, discusses findings from the V-INCEPTION trial evaluating inclisiran for low-density lipoprotein cholesterol (LDL-C) management after myocardial infarction, highlighting its real-world effectiveness, tolerability, and potential for integration into pharmacist-led lipid care pathways.

New research reveals that GLP-1 receptor agonists like semaglutide may significantly reduce stroke impacts and improve recovery outcomes.

RSV hospitalization in older adults links to increased cardiovascular events, highlighting the need for vigilant monitoring and vaccination strategies.

By targeting aldosterone in a 2-dose regimen, baxdrostat effectively lowers mean seated systolic blood pressure in patients with difficult-to-treat hypertension.

A recent study reveals Mvasi's comparable safety profile to Avastin for retinal diseases, highlighting the need for on-label biosimilars in ophthalmology.

Both vaccine and nonvaccine serotypes were identified as being resistant to critical antimicrobial treatments for pneumococcal disease.

Hormonal contraceptives present a nuanced risk-benefit profile, slightly increasing breast and cervical cancer risk while significantly reducing ovarian and endometrial cancer rates.

Understanding the regulatory landscape can maximize pharmacists' roles while ensuring legal compliance.

Pharmacists guide pregnant women in balancing depression treatment with SSRI safety, addressing risks of untreated depression and neonatal adaptation syndrome.

Luspatercept shows promise in reducing transfusion dependence for myelofibrosis-associated anemia, despite not meeting primary trial end points.

Astegolimab shows promise in reducing chronic obstructive pulmonary disease (COPD) exacerbations, offering hope for improved management of this debilitating lung disease.